Slanetz Priscilla J, Grandpre Lauren E, Yeh Eren D, Kopans Daniel B, Mendel Jeffrey B
Division of Breast Imaging, Department of Radiology, Caritas St. Elizabeth's Medical Center, Boston, Massachusetts 02135, USA.
Breast J. 2004 Jan-Feb;10(1):27-32. doi: 10.1111/j.1524-4741.2004.09606.x.
It has been established that hormone replacement therapy (HRT) increases breast tissue density on mammography in up to 30% of women receiving treatment. The effects of selective estrogen receptor modulators (SERMs) on breast tissue have received limited attention, although there have been several reports of tamoxifen decreasing mammographic tissue density in some women undergoing adjuvant or prophylactic breast cancer treatment. We report a case of a premenopausal woman treated with tamoxifen for 5 years whose mammographic density decreased while on tamoxifen and returned to her baseline density following termination of the drug. A regression of breast tissue may be reflective of sensitivity to tamoxifen and possibly, indicative of therapeutic benefit associated with treatment. Furthermore, induction of a more radiolucent pattern by tamoxifen may independently benefit women by enhancing mammographic detection. The clinical significance of resumption of a dense breast pattern following discontinuation of tamoxifen remains to be determined.
已证实，激素替代疗法（HRT）会使高达30%接受治疗的女性在乳房X光检查中出现乳腺组织密度增加。选择性雌激素受体调节剂（SERM）对乳腺组织的影响受到的关注有限，尽管有几份报告称他莫昔芬可降低一些接受辅助性或预防性乳腺癌治疗的女性的乳房X光检查组织密度。我们报告一例绝经前女性，她接受他莫昔芬治疗5年，在服用他莫昔芬期间乳房X光检查密度降低，停药后恢复到基线密度。乳腺组织的消退可能反映对他莫昔芬的敏感性，也可能表明与治疗相关的治疗益处。此外，他莫昔芬诱导出更透亮的模式可能通过增强乳房X光检查检测而使女性独立受益。停用他莫昔芬后乳房致密模式恢复的临床意义仍有待确定。
